Drug Detail

Information about R1507

Generic Name
IND	R1507
Brand Name (US)
Manufacturer	Hoffmann-La Roche
Drug Type	monoclonal antibody
Delivery	Intravenous
Approval Status	Development discontinued
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths
Drug Category	IGF1R inhibitor

This drug advanced as far as phase II trials. Our understanding is that development has been halted.
R1507 is a fully human antibody created by Genmab under a collaboration with Roche. R1507 was selected from a large panel of antibodies and targets the Insulin-like Growth factor-1 Receptor (IGF-1R). The IGF-1R molecule has been shown to be important in tumor growth and protecting tumor cells from being killed. IGF-1R is over-expressed on a variety of tumors including breast, colon, prostate, lung, skin and pancreatic cancers and is a well validated target for an antibody therapeutic approach.
IGF1R is overexpressed in 2/3 of wild-type GISTs and almost all pediatric GISTs. Patients with wild-type GIST and pediatric GIST may be good candidates for a trial with inhibitors of IGF1R.